Ajani et al (2009) also performed immunohistochemical analysis of EGFR and reported expression in 86% of patients with anal cancer, but no significant correlation was observed between the degree of EGFR staining and DFS. One study detected EGFR using immunohistochemistry in 55% of anal SCCs. They also performed fluorescent in situ hybridisation (FISH) to assess EGFR gene copy numbers (Alvarez et al, 2006). There was no correlation between EGFR status and clinicopathological parameters. Furthermore, there was a lack of concordance between the two detection techniques (Alvarez et al, 2006). Here, EGFR is linked to anal carcinoma.